| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22012 |
| Drug | Finerenone |
| Brand | Kerendia® |
| Indication | For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. |
| Assessment Process | |
| Rapid review commissioned | 21/02/2022 |
| Rapid review completed | 15/03/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of finerenone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/04/2022 |
| Pre-submission consultation with Applicant | 24/05/2022 |
| Full submission received from Applicant | 10/11/2022 |
| Preliminary review sent to Applicant | 24/02/2023 |
| NCPE assessment re-commenced | 29/03/2023 |
| Follow-up to preliminary review sent to Applicant | 08/05/2023 |
| NCPE assessment re-commenced | 18/05/2023 |
| Factual accuracy sent to Applicant | 12/06/2023 |
| NCPE assessment re-commenced | 04/07/2023 |
| NCPE assessment completed | 22/08/2023 |
| NCPE assessment outcome | The NCPE recommends that finerenone (Kerendia®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
